Valuation ·
Neurocrine Biosciences 2026
Relative valuation of Neurocrine Biosciences (NBIX) against ten neuroscience and specialty biopharma peers: P/E, EV/EBITDA, EV/Sales and PEG multiples, peer statistics, and a cross-check against Yahoo Finance.
| Ticker | Company | Market Cap ($m) | EV ($m) | EPS CAGR 2y | P/E TTM | P/E FY0 | P/E FY+1 | EV/EBITDA TTM | EV/Sales TTM | PEG (P/E FY0 / g) |
| NBIX | Neurocrine Biosciences, Inc. | 14,068.25 | 13,841.05 | 36.9% | 20.29 | 13.57 | 11.56 | 15.99 | 4.10 | 0.37 |
| ACAD | ACADIA Pharmaceuticals Inc. | 3,563.28 | 2,680.66 | 3.5% | 9.32 | 34.51 | 23.27 | 27.24 | 2.35 | 9.92 |
| AXSM | Axsome Therapeutics, Inc. | 10,218.97 | 10,123.82 | 41.69 | 13.04 | |||||
| SUPN | Supernus Pharmaceuticals, Inc. | 2,483.84 | 2,151.94 | 36.5% | 16.63 | 9.57 | 2.59 | 0.46 | ||
| JAZZ | Jazz Pharmaceuticals plc | 15,446.42 | 17,655.92 | 75.3% | 16.41 | 9.54 | 9.24 | 10.92 | 3.84 | 0.13 |
| ALKS | Alkermes plc | 6,853.13 | 7,896.71 | -7.2% | 107.50 | 32.04 | 22.59 | 28.57 | 5.05 | |
| INCY | Incyte Corporation | 25,112.22 | 20,614.75 | 14.3% | 15.78 | 35.85 | 13.94 | 9.97 | 3.54 | 2.51 |
| BMRN | BioMarin Pharmaceutical Inc. | 11,664.75 | 14,500.71 | 45.0% | 162.86 | 12.20 | 9.10 | 37.60 | 4.26 | 0.27 |
| UTHR | United Therapeutics Corporation | 20,392.38 | 16,788.98 | 1.3% | 17.01 | 18.24 | 16.63 | 10.01 | 5.32 | 14.17 |
| EXEL | Exelixis, Inc. | 14,410.98 | 13,192.60 | 17.6% | 18.29 | 16.24 | 13.65 | 12.93 | 5.42 | 0.92 |
| HALO | Halozyme Therapeutics, Inc. | 12,927.42 | 14,843.07 | 58.3% | 34.00 | 13.28 | 10.96 | 20.66 | 8.92 | 0.23 |